Chih-Yi “Andy” Liao, MD

Articles by Chih-Yi “Andy” Liao, MD

Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.

Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma

ByChih-Yi “Andy” Liao, MD

September 29th 2026

Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.

Latest Updated Articles

Trending on CancerNetwork

Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer

Exploring Advancements in Targeting KRAS in Cholangiocarcinoma

Hypofractionated PMRT Shows Durable 10-Year Control in High-Risk Breast Cancer

Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy

Sequencing CAR T Therapy and Bispecifics in Follicular and Mantle Cell Lymphoma